Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Promotions
AI
Gate AI
Your all-in-one conversational AI partner
Gate AI Bot
Use Gate AI directly in your social App
GateClaw
Gate Blue Lobster, ready to go
Gate for AI Agent
AI infrastructure, Gate MCP, Skills, and CLI
Gate Skills Hub
10K+ Skills
From office tasks to trading, the all-in-one skill hub makes AI even more useful.
GateRouter
Smartly choose from 40+ AI models, with 0% extra fees
Baird Lowers Bright Minds Biosciences Inc. (DRUG) Price Target to $126, Maintains Outperform Rating Ahead of Upcoming Trials
Baird Lowers Bright Minds Biosciences Inc. (DRUG) Price Target to $126, Maintains Outperform Rating Ahead of Upcoming Trials
Laiba Immad
Thu, February 19, 2026 at 11:31 AM GMT+9 2 min read
In this article:
DRUG
-4.30%
Bright Minds Biosciences Inc. (NASDAQ:DRUG) is among the 7 Most Promising Psychedelic Stocks According to Hedge Funds.
Baird Lowers Bright Minds Biosciences Inc. (DRUG) Price Target to $126, Maintains Outperform Rating Ahead of Upcoming Trials
Bright Minds Biosciences Inc. (NASDAQ:DRUG) is among the most promising stocks.
TheFly reported on February 13 that Baird lowered its price target for DRUG to $126 from $142 and maintained an Outperform rating on the shares. The update follows the company’s fourth-quarter results and reflects adjustments to the firm’s model as Bright Minds prepares for upcoming epilepsy and PWS trial initiations.
Separately, earlier on January 6, Bright Minds Biosciences Inc. (NASDAQ:DRUG) announced positive topline results from its Phase 2 BREAKTHROUGH trial, which is assessing BMB-101. It is a selective 5-HT2C biased agonist, in adults with developmental and encephalopathic epilepsies (DEE) and drug-resistant absence seizures. In both patient cohorts, the study met its major effectiveness goals, which show significant reductions in seizures while also preserving a good safety and tolerability profile.
The reports show that the patients in the DEE group saw a median reduction of 63.3% in severe motor seizures, and a median reduction of 73.1% in seizures lasting three seconds or more in the Absence Seizure cohort. Beyond seizure management, the research also showed a noteworthy 90% increase in REM sleep without impacting overall sleep length, indicating possible cognitive advantages.
Bright Minds Biosciences Inc. (NASDAQ:DRUG) is a biotech psychedelics company developing next‑generation serotonin‑based therapies that harness the therapeutic benefits of psychedelic compounds for treatment‑resistant depression, epilepsy, PTSD, and other neuropsychiatric disorders, aiming to improve safety and efficacy over first‑generation psychedelics.
While we acknowledge the potential of DRUG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
****READ NEXT: 12 Unstoppable Dividend Stocks to Buy According to Analysts ****and Dividend Champions, Contenders and Challengers list: 15 Highest Yielding Stocks.
Disclosure: None.
Terms and Privacy Policy
Privacy Dashboard
More Info